代谢功能障碍相关脂肪性肝病:新命名对AASLD非酒精性脂肪性肝病实践指南的影响及更新
本文评述了在新命名改为脂肪性肝病及其亚类后,临床医生和利益相关者如何使用已发表的AASLD非酒精性脂肪性肝病实践指南。新术语使读者在阅读指南时可互换使用MASLD替代NAFLD、MASH替代NASH,该指南适用于MASLD患者的诊断、风险分层和管理。
要点
- MASLD可替代NAFLD、MASH可替代NASH互换使用。
- AASLD NAFLD实践指南适用于MASLD患者的诊断、风险分层和管理。
- 本文为NAFLD实践指南的配套文章,帮助其在新命名下的临床应用。
核心结论
- 新命名下,MASLD可替代NAFLD、MASH可替代NASH互换使用,AASLD NAFLD实践指南仍适用于MASLD患者的诊断、风险分层和管理。
研究设计与样本
- 本文为评述文章,讨论临床医生和利益相关者如何在新命名下使用已发表的AASLD NAFLD实践指南。
主要发现
- 新术语使读者在阅读NAFLD实践指南时可互换使用MASLD替代NAFLD、MASH替代NASH。
- 该指南文件适用于MASLD患者的诊断、风险分层和管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of Liver Diseases nonalcoholic fatty liver disease (AASLD NAFLD) Practice Guidance in light of the change in the nomenclature to steatotic liver disease and its subcategories. The new terminologies explained in this commentary make it easier for the readers to interchangeably use metabolic dysfunction-associated steatotic liver disease (MASLD) in place of NAFLD and metabolic-dysfunction associated steatohepatitis (MASH) instead of nonalcoholic steatohepatitis (NASH), respectively, as they read the NAFLD Practice Guidance. The guidance document is relevant and can be utilized for the diagnosis, risk stratification, and management of patients with MASLD. This commentary serves as an accompanying article to the NAFLD Practice Guidance and helps it clinical application in the light of the new nomenclature.
引用
- Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2023. PMID: 38445559. doi:10.1097/HEP.0000000000000670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。